Derek DiRocco
Directeur/Bestuurslid bij MINERALYS THERAPEUTICS, INC.
Vermogen: 165 800 $ op 30-04-2024
Actieve functies van Derek DiRocco
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
89BIO, INC. | Directeur/Bestuurslid | 01-04-2018 | - |
Independent Dir/Board Member | 01-04-2018 | - | |
WEREWOLF THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-12-2020 | - |
Independent Dir/Board Member | 01-12-2020 | - | |
ACRIVON THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-11-2021 | - |
Independent Dir/Board Member | 01-11-2021 | - | |
MINERALYS THERAPEUTICS, INC. | Directeur/Bestuurslid | 08-05-2022 | - |
Independent Dir/Board Member | 08-05-2022 | - | |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Analyst-Equity | - | - |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Directeur/Bestuurslid | - | - |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01-12-2017 | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | - | - |
Suzhou Connect Biopharma Co. Ltd.
Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Directeur/Bestuurslid | - | - |
Loopbaan van Derek DiRocco
Eerdere bekende functies van Derek DiRocco
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░ ░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Opleiding van Derek DiRocco
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
University of Washington | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 13 |
Verenigd Koninkrijk | 3 |
China | 3 |
Operationeel
Director/Board Member | 13 |
Independent Dir/Board Member | 8 |
Analyst-Equity | 1 |
Sectoraal
Health Technology | 14 |
Finance | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 10 |
---|---|
Health Technology | |
89BIO, INC. | Health Technology |
ITEOS THERAPEUTICS, INC. | Health Technology |
WEREWOLF THERAPEUTICS, INC. | Health Technology |
CONNECT BIOPHARMA HOLDINGS LIMITED | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
ACRIVON THERAPEUTICS, INC. | Health Technology |
MINERALYS THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Finance |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Health Technology |
Suzhou Connect Biopharma Co. Ltd.
Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Health Technology |
- Beurs
- Insiders
- Derek DiRocco
- Ervaring